Freeport-McMoRan Inc. Total Cost of Revenue decreased by 0.8% to $4.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.5%, from $4.22B to $4.58B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 7.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.55B | $3.55B | $3.72B | $3.64B | $3.53B | $3.90B | $4.02B | $3.56B | $4.10B | $4.09B | $3.95B | $4.44B | $4.38B | $4.68B | $4.30B | $4.22B | $4.95B | $4.83B | $4.62B | $4.58B |
| QoQ Change | — | +0.0% | +4.8% | -2.3% | -3.1% | +10.5% | +3.2% | -11.4% | +14.9% | -0.2% | -3.4% | +12.4% | -1.2% | +6.7% | -8.2% | -1.7% | +17.2% | -2.4% | -4.4% | -0.8% |
| YoY Change | — | — | — | — | -0.6% | +9.8% | +8.1% | -2.1% | +16.1% | +4.8% | -1.8% | +24.6% | +7.0% | +14.5% | +8.8% | -4.9% | +12.9% | +3.3% | +7.5% | +8.5% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Rod & Refining | $1.69B | $1.56B | $1.47B | $1.62B | $1.69B | $1.77B | $1.77B | $2.05B |
| Atlantic Copper Smelting & Refining | $859.00M | $754.00M | $649.00M | $734.00M | $791.00M | $753.00M | $821.00M | $929.00M |
| Grasberg Segment | — | — | — | — | — | — | — | $710.00M |
| Morenci | — | — | — | — | — | — | — | $437.00M |
| Cerro Verde | $632.25M | $632.25M | — | — | — | — | — | — |
| Molybdenum | $134.00M | $140.00M | $137.00M | $122.00M | $128.00M | $150.00M | — | — |
| Total | $4.38B | $4.68B | $4.30B | $4.22B | $4.95B | $4.83B | $4.62B | $4.58B |
Molybdenum was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 |
|---|---|---|---|---|---|---|---|---|
| North America | $1.17B | $1.22B | $1.15B | $1.30B | $1.32B | $1.21B | $1.21B | $1.39B |
| South America | $822.00M | $773.00M | $860.00M | $817.00M | $780.00M | $788.00M | $768.00M | $802.00M |
| Total | $3.95B | $4.44B | $4.38B | $4.68B | $4.30B | $4.22B | $4.95B | $4.83B |
North America, South America were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.